A Phase 2 interventional study of CDR132L and Placebo to CDR132L in Myocardial Infarction, Acute and Heart Failure, Left Sided, sponsored by Cardior Pharmaceuticals GmbH. Completed at 49 sites in 8 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Cardior Pharmaceuticals GmbH (part of Novo Nordisk A/S) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Myocardial Infarction with a site in Poland — 17 open to participants now, 21 under way, 5 of them phase 3. Myocardial Infarction · Poland.
Among the 89 studies in Myocardial Infarction with a site in Poland, this one is the 50th largest by enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 in phase 2, and was the 71st registered.
2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.
Browse Myocardial Infarction studies →17 of the 89 studies in Myocardial Infarction with a site in Poland are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Poland, Ireland, Latvia and 2 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
Abcentra · Sites in Poland, United States, Czechia and 6 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
MEDICOVER SP Z O.O. · Sites in Poland
Ages 18–85
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 30 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 294 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 1,012 across the 77 interventional studies, 490 across the 12 observational. Of the 65 that completed or were terminated, 29 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cardior Pharmaceuticals GmbH, one of the names counted as Novo Nordisk A/S. Under that name alone:
Cardior Pharmaceuticals GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.
Novo Nordisk A/S has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
9 of the studies in Myocardial Infarction with a site in Poland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07203846Collegium Medicum w BydgoszczyModulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor | 2026-12-31 |
| NCT06956807ViscofanSafety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells | 2026-12-31 |
| NCT07617376Wroclaw Medical UniversityPre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 89 studies in Myocardial Infarction with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (to occur at least 3 days after MI diagnosis), a 6-month double-blind period, and a 6-month extension period with the End of Study (EOS) Visit at Day 360/Month 12.
Two dosages of CDR132L will be tested against placebo on their effects on patients, who just had a heart attack in addition to standard care. The aim of the study is to show that CDR132L is safe and effective to improve heart failure in such patients.
Main Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
Drug: CDR132L
CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
Drug: CDR132L
Placebo intravenous in single dose on Day 1, Day 29 and Day 57
Drug: Placebo to CDR132L
CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
Placebo to CDR132L
Percent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6
Percent change from baseline in LVESVI at Month 6 is presented. LVESVI is considered one of the standard echocardiography (ECHO) markers for assessing risks in ischemic heart failure (HF). The ECHO was performed to assess LVESVI.
Time frame: Baseline (Day 1), Month 6
Number of Treatment Emergent Adverse Events (TEAEs)
Number of TEAEs were presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment.
Time frame: Up to 12 months
Number of Treatment Emergent Serious Adverse Events (TESAEs)
Number of TESAEs are presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: a) results in death, b) is life-threatening, c) requires inpatient hospitalization or prolongation of existing hospitalization, d) results in persistent disability/incapacity, e) is a congenital anomaly/birth defect, f) other situations where medical or scientific judgement should be excercised.
Time frame: Up to 12 months
Number of Participants With Abnormalities in Clinically Relevant Laboratory Assessments
Number of participants with abnormalities in clinically relevant laboratory assessments up to month 6 is presented. Laboratory investigation included hematology, chemistry, coagulation and urinalysis parameters. Clinical relevance was decided by the investigator.
Time frame: At month 6
Number of Participants With Clinically Relevant Laboratory Abnormalities in Vital Signs Parameters
Number of participants with clinically relevant laboratory abnormalities in vital signs parameters on month 12 is presented. Vital signs included oral body temperature, systolic blood pressure, diastolic blood pressure, and pulse rate. Clinical relevance was decided by the investigator.
Time frame: At month 12
Number of Participants With Clinically Relevant Laboratory Abnormalities in ECG Parameters
Number of participants with clinically relevant laboratory abnormalities in ECG parameters at month 12 is presented. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position. The parameters included heart rate (HR), Pulse Rate, QRS, QT interval. Clinical relevance was decided by the investigator.
Time frame: At month 12
Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 3
Absolute change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D echocardiography (ECHO) was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
Time frame: Baseline (Day 1), Month 3
Absolute Change From Baseline in LVEF at Month 6
Absolute change from baseline in LVEF at month 6 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in LVEF at Month 12
Absolute change from baseline in LVEF at month 12 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
Time frame: Baseline (Day 1), Month 12
Relative Change From Baseline in LVEF at Month 3
Relative change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
Time frame: Baseline (Day 1), Month 3
Relative Change From Baseline in LVEF at Month 6
Relative change from baseline in LVEF at month 6 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
Time frame: Baseline (Day 1), Month 6
Relative Change From Baseline in LVEF at Month 12
Relative change from baseline in LVEF at month 12 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
Time frame: Baseline (Day 1), Month 12
Absolute Change From Baseline in LVESVI at Month 3
Absolute change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
Time frame: Baseline (Day 1), Month 3
Absolute Change From Baseline in LVESVI at Month 6
Absolute change from baseline in LVESVI at month 6 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in LVESVI at Month 12
Absolute change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
Time frame: Baseline (Day 1), Month 12
Relative Change From Baseline in LVESVI at Month 3
Relative change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
Time frame: Baseline (Day 1), Month 3
Relative Change From Baseline in LVESVI at Month 12
Relative change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
Time frame: Baseline (Day 1), Month 12
Absolute Change From Baseline in Troponin T at Month 3
Absolute change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by high-sensitivity cardiac troponin (hs-cTn) assays.
Time frame: Baseline (Day 1), Month 3
Absolute Change From Baseline in Troponin T at Month 6
Absolute change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in Troponin T at Month 12
Absolute change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.
Time frame: Baseline (Day 1), Month 12
Relative Change From Baseline in Troponin T at Month 3
Relative change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by hs-cTn assays.
Time frame: Baseline (Day 1), Month 3
Relative Change From Baseline in Troponin T at Month 6
Relative change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.
Time frame: Baseline (Day 1), Month 6
Relative Change From Baseline in Troponin T at Month 12
Relative change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.
Time frame: Baseline (Day 1), Month 12
Absolute Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Month 1
Absolute change from baseline in NT-proBNP at month 1 is presented.
Time frame: Baseline (Day 1), Month 1
Absolute Change From Baseline in NT-proBNP at Month 2
Absolute change from baseline in NT-proBNP at month 2 is presented.
Time frame: Baseline (Day 1), Month 2
Absolute Change From Baseline in NT-proBNP at Month 3
Absolute change from baseline in NT-proBNP at month 3 is presented.
Time frame: Baseline (Day 1), Month 3
Absolute Change From Baseline in NT-proBNP at Month 6
Absolute change from baseline in NT-proBNP at month 6 is presented.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in NT-proBNP at Month 12
Absolute change from baseline in NT-proBNP at month 12 is presented.
Time frame: Baseline (Day 1), Month 12
Relative Change From Baseline in NT-proBNP at Month 1
Relative change from baseline in NT-proBNP at month 1 is presented.
Time frame: Baseline (Day 1), Month 1
Relative Change From Baseline in NT-proBNP at Month 2
Relative change from baseline in NT-proBNP at month 2 is presented.
Time frame: Baseline (Day 1), Month 2
Relative Change From Baseline in NT-proBNP at Month 3
Relative change from baseline in NT-proBNP at month 3 is presented.
Time frame: Baseline (Day 1), Month 3
Relative Change From Baseline in NT-proBNP at Month 6
Relative change from baseline in NT-proBNP at month 6 is presented.
Time frame: Baseline (Day 1), Month 6
Relative Change From Baseline in NT-proBNP at Month 12
Relative change from baseline in NT-proBNP at month 12 is presented.
Time frame: Baseline (Day 1), Month 12
Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 6
Absolute change from baseline in mean Kansas City Cardiomyopathy Questionnaire (KCCQ) score (overall summary score) at month 6 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Sum-mary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 12
Absolute change from baseline in mean KCCQ score (overall summary score) at month 12 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Summary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.
Time frame: Baseline (Day 1), Month 12
Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 6
Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 12
Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.
Time frame: Baseline (Day 1), Month 12
Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 6
Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 12
Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.
Time frame: Baseline (Day 1), Month 12
Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 6
Absolute change from baseline in KCCQ subdomain score (quality of life) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.
Time frame: Baseline (Day 1), Month 6
Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 12
Absolute change from baseline in KCCQ subdomain score (quality of life) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.
Time frame: Baseline (Day 1), Month 12
The trial was conducted in 8 countries (Netherlands, Spain, Germany, Czech Republic, Poland, United Kingdom, Greece, and Hungary).
| Milestone | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Started | 98 | 98 | 98 |
| Modified intent-to-treat (mitt) analysis set | 90 | 94 | 96 |
| Safety analysis set (saf) | 91 | 94 | 95 |
| Completed | 82 | 86 | 91 |
| Not completed | 16 | 12 | 7 |
| Withdrew: Withdrawal by subject | 8 | 9 | 4 |
| Withdrew: Subject non-compliance with study schedule | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Physician decision | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Death | 5 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
Number of TEAEs were presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment.
| Events | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 81 | 116 | 120 |
Number of TESAEs are presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: a) results in death, b) is life-threatening, c) requires inpatient hospitalization or prolongation of existing hospitalization, d) results in persistent disability/incapacity, e) is a congenital anomaly/birth defect, f) other situations where medical or scientific judgement should be excercised.
| Events | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Number of Treatment Emergent Serious Adverse Events (TESAEs) | 10 | 13 | 10 |
Number of participants with abnormalities in clinically relevant laboratory assessments up to month 6 is presented. Laboratory investigation included hematology, chemistry, coagulation and urinalysis parameters. Clinical relevance was decided by the investigator.
| Participants | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Number of Participants With Abnormalities in Clinically Relevant Laboratory Assessments | 0 | 0 | 0 |
Number of participants with clinically relevant laboratory abnormalities in vital signs parameters on month 12 is presented. Vital signs included oral body temperature, systolic blood pressure, diastolic blood pressure, and pulse rate. Clinical relevance was decided by the investigator.
| Participants | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Number of Participants With Clinically Relevant Laboratory Abnormalities in Vital Signs Parameters | 0 | 0 | 0 |
Number of participants with clinically relevant laboratory abnormalities in ECG parameters at month 12 is presented. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position. The parameters included heart rate (HR), Pulse Rate, QRS, QT interval. Clinical relevance was decided by the investigator.
| Participants | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Number of Participants With Clinically Relevant Laboratory Abnormalities in ECG Parameters | 0 | 0 | 0 |
Absolute change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D echocardiography (ECHO) was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
| Percentage of LVEF | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 3 | 7.079 ± 9.1251 | 7.249 ± 8.2353 | 8.158 ± 8.1040 |
Absolute change from baseline in LVEF at month 6 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
| Percentage of LVEF | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in LVEF at Month 6 | 7.204 ± 8.9827 | 7.702 ± 8.7903 | 8.345 ± 8.9602 |
Absolute change from baseline in LVEF at month 12 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
| Percentage of LVEF | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in LVEF at Month 12 | 7.832 ± 10.2149 | 7.238 ± 9.6505 | 9.996 ± 10.3128 |
Relative change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
| Percentage change in LVEF | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in LVEF at Month 3 | 20.344 ± 27.9785 | 21.416 ± 26.8197 | 26.864 ± 43.5875 |
Relative change from baseline in LVEF at month 6 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
| Percentage change in LVEF | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in LVEF at Month 6 | 20.702 ± 26.4065 | 23.358 ± 30.4490 | 27.218 ± 45.2933 |
Relative change from baseline in LVEF at month 12 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.
| Percentage change in LVEF | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in LVEF at Month 12 | 22.564 ± 30.2719 | 22.745 ± 33.4579 | 33.301 ± 51.7346 |
Absolute change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
| milliliter per square meter (mL/m^2) | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in LVESVI at Month 3 | -2.881 ± 10.0057 | -4.743 ± 10.0689 | -4.741 ± 9.3632 |
Absolute change from baseline in LVESVI at month 6 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
| mL/m^2 | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in LVESVI at Month 6 | -3.251 ± 11.1720 | -4.364 ± 11.9719 | -4.620 ± 9.7796 |
Absolute change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
| mL/m^2 | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in LVESVI at Month 12 | -3.556 ± 12.9191 | -2.934 ± 13.8075 | -5.835 ± 12.7819 |
Relative change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
| Percentage change in LVESVI | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in LVESVI at Month 3 | -6.750 ± 21.5157 | -9.592 ± 17.6281 | -9.916 ± 18.6656 |
Relative change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.
| Percentage change in LVESVI | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in LVESVI at Month 12 | -7.595 ± 27.1199 | -3.977 ± 26.1962 | -11.340 ± 25.2110 |
Absolute change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by high-sensitivity cardiac troponin (hs-cTn) assays.
| nanograms per liter (ng/L) | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in Troponin T at Month 3 | -491.170 ± 1048.4929 | -614.101 ± 1191.9920 | -635.094 ± 1069.5844 |
Absolute change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.
| ng/L | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in Troponin T at Month 6 | -495.783 ± 1049.7521 | -616.713 ± 1192.9610 | -648.956 ± 1059.8187 |
Absolute change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.
| ng/L | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in Troponin T at Month 12 | -532.980 ± 1092.3140 | -597.288 ± 1202.6642 | -669.203 ± 1089.2607 |
Relative change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by hs-cTn assays.
| Percentage change in troponin T | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in Troponin T at Month 3 | -70.517 ± 41.4856 | -70.113 ± 48.7907 | -65.982 ± 141.6371 |
Relative change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.
| Percentage change in troponin T | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in Troponin T at Month 6 | -73.433 ± 38.5429 | -67.927 ± 101.6616 | -82.391 ± 26.2483 |
Relative change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.
| Percentage change in troponin T | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in Troponin T at Month 12 | -78.753 ± 35.1892 | -78.671 ± 32.7166 | -83.657 ± 26.1048 |
Absolute change from baseline in NT-proBNP at month 1 is presented.
| picograms per milliliter (pg/mL) | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Month 1 | -0.1444 ± 0.62513 | -0.1892 ± 0.48722 | -0.1384 ± 0.56701 |
Absolute change from baseline in NT-proBNP at month 2 is presented.
| pg/mL | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in NT-proBNP at Month 2 | -0.5252 ± 0.70912 | -0.6387 ± 0.67982 | -0.5467 ± 0.65068 |
Absolute change from baseline in NT-proBNP at month 3 is presented.
| pg/mL | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in NT-proBNP at Month 3 | -0.7991 ± 0.80655 | -0.8523 ± 0.78089 | -0.7210 ± 0.77963 |
Absolute change from baseline in NT-proBNP at month 6 is presented.
| pg/mL | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in NT-proBNP at Month 6 | -1.1076 ± 0.87256 | -1.1231 ± 0.90866 | -0.9706 ± 0.87285 |
Absolute change from baseline in NT-proBNP at month 12 is presented.
| pg/mL | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in NT-proBNP at Month 12 | -1.2172 ± 0.94119 | -1.4541 ± 1.00285 | -1.2894 ± 0.86983 |
Relative change from baseline in NT-proBNP at month 1 is presented.
| Percentage change in NT-proBNP | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in NT-proBNP at Month 1 | -1.6895 ± 8.90865 | -2.5174 ± 6.72629 | -1.6953 ± 8.30762 |
Relative change from baseline in NT-proBNP at month 2 is presented.
| Percentage change in NT-proBNP | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in NT-proBNP at Month 2 | -7.1409 ± 10.09998 | -8.6990 ± 9.09517 | -7.5912 ± 9.44475 |
Relative change from baseline in NT-proBNP at month 3 is presented.
| Percentage change in NT-proBNP | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in NT-proBNP at Month 3 | -10.9714 ± 10.91364 | -11.5696 ± 10.50248 | -9.9554 ± 11.20355 |
Relative change from baseline in NT-proBNP at month 6 is presented.
| Percentage change in NT-proBNP | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in NT-proBNP at Month 6 | -15.3272 ± 11.68935 | -15.3277 ± 12.20384 | -13.3489 ± 12.89651 |
Relative change from baseline in NT-proBNP at month 12 is presented.
| Percentage change in NT-proBNP | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Relative Change From Baseline in NT-proBNP at Month 12 | -16.7190 ± 12.91568 | -19.4944 ± 12.52067 | -17.9837 ± 11.88971 |
Absolute change from baseline in mean Kansas City Cardiomyopathy Questionnaire (KCCQ) score (overall summary score) at month 6 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Sum-mary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 6 | 11.698 ± 18.3475 | 7.821 ± 21.5032 | 7.638 ± 19.1797 |
Absolute change from baseline in mean KCCQ score (overall summary score) at month 12 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Summary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 12 | 12.349 ± 20.9457 | 10.255 ± 20.7294 | 8.261 ± 19.3870 |
Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 6 | 9.77 ± 18.815 | 5.98 ± 20.462 | 6.14 ± 19.981 |
Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 12 | 9.90 ± 19.671 | 8.24 ± 19.309 | 6.37 ± 18.719 |
Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 6 | 8.46 ± 20.648 | 7.59 ± 21.876 | 4.37 ± 24.093 |
Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 12 | 8.16 ± 22.014 | 8.91 ± 23.038 | 5.25 ± 22.807 |
Absolute change from baseline in KCCQ subdomain score (quality of life) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 6 | 16.09 ± 24.372 | 10.37 ± 27.732 | 11.93 ± 23.116 |
Absolute change from baseline in KCCQ subdomain score (quality of life) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.
| Score on a scale | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 12 | 17.60 ± 26.815 | 13.58 ± 27.497 | 12.45 ± 25.473 |
Percent change from baseline in LVESVI at Month 6 is presented. LVESVI is considered one of the standard echocardiography (ECHO) markers for assessing risks in ischemic heart failure (HF). The ECHO was performed to assess LVESVI.
| Percentage change in LVESVI | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Percent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6 | -7.611 ± 23.8747 | -8.364 ± 19.8437 | -9.824 ± 19.6001 |
Collected over Up to 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 5/98 (5.1%) | 9/91 (9.9%) | 3/91 (3.3%) |
| CDR132L 5 mg/kg | 0/98 (0%) | 9/94 (9.6%) | 5/94 (5.3%) |
| CDR132L 10 mg/kg | 1/98 (1%) | 8/95 (8.4%) | 4/95 (4.2%) |
| Event | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| Cardiac arrestCardiac disorders | 2/91 | 0/94 | 0/95 |
| Cardiac failureCardiac disorders | 1/91 | 0/94 | 2/95 |
| Acute coronary syndromeCardiac disorders | 1/91 | 0/94 | 0/95 |
| Cardiorenal syndromeCardiac disorders | 1/91 | 0/94 | 0/95 |
| Coronary artery stenosisCardiac disorders | 1/91 | 1/94 | 0/95 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/91 | 0/94 | 0/95 |
| Non-cardiac chest painGeneral disorders | 1/91 | 1/94 | 0/95 |
| Renal failureRenal and urinary disorders | 1/91 | 0/94 | 1/95 |
| Urinary tract infectionInfections and infestations | 1/91 | 0/94 | 0/95 |
| Acute myocardial infarctionCardiac disorders | 0/91 | 1/94 | 0/95 |
| Event | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/91 | 5/94 | 4/95 |
A modified Intent-to-Treat (mITT) analysis set has been defined to include all randomized subjects who receive at least 1 dose of study drug (CDR132L or placebo).
| Age, Continuous(Years) | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 61.0 ± 10.44 | 60.8 ± 10.12 | 61.0 ± 10.11 | 60.9 ± 10.18 |
| Sex: Female, Male(Participants) | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg | Total |
|---|---|---|---|---|
| Female | 9 | 11 | 15 | 35 |
| Male | 81 | 83 | 81 | 245 |
| Race (NIH/OMB)(Participants) | Placebo | CDR132L 5 mg/kg | CDR132L 10 mg/kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 88 | 90 | 91 | 269 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 4 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Sep 2024, 26 months.
Results were first posted in Aug 2026, 1 year 11 months after primary completion. A results delay was requested in Jan 2025.
Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CDR132L